SAN FRANCISCO, Feb. 12, 2019 /PRNewswire-PRWeb/ -- Innovaderm Research, Inc., an innovative clinical research organization (CRO) specializing in dermatology, has finalized a deal to extend their use of Medrio, the leading provider of eClinical technology for early-phase pharma, medical device, and diagnostics clinical trials, through 2023. The CRO has been a regular Medrio customer for over nine years, primarily using the software in Phase I, Phase IIA, or Phase IIB pharma studies. With the new agreement, Innovaderm will continue to have access to a host of resources that will better enable them to deliver sponsor satisfaction and grow their business.
The agreement signifies Medrio's status as a preferred electronic data capture (EDC) provider at Innovaderm. "We've long experienced consistent satisfaction from study sponsors when using Medrio," commented Eric Hardy, Director of Data Management and Statistics at Innovaderm. "We recommend working with Medrio to our sponsor clients, particularly in early phase trials, and when given the discretion to choose the EDC for our trials, we favor Medrio."
Innovaderm cited numerous factors in their decision to commit to this significant extension of their relationship with Medrio. These factors include:
- The high performance of the Medrio system in early phase pharma studies
- The flexibility and functionality of Medrio EDC
- Medrio's ability to offer high-quality products and services at a low total cost of ownership – a key benefit for organizations conducting early phase studies
"The success of Innovaderm is a perfect example of why Medrio delivers the most benefit in early phase clinical trials," said Mike Novotny, founder and CEO at Medrio. "With this new agreement, we look forward to continuing to serve one of our longest-tenured customers as they help their sponsor clients bring innovative medical products to market."
About Innovaderm Research, Inc.
Innovaderm Research is a prominent Contract Research Organization (CRO) specialized in Dermatology and focused on clinical studies of phase I, II, III & IV. Founded in 1999, the company provides a broad range of services including study design, protocol development, site selection and patient recruitment, regulatory and ethics submissions, clinical trial management, clinical monitoring, data management, biostatistics, medical monitoring and medical writing. Innovaderm prides itself on managing its activities in accordance to current Good Clinical Practice (GCP) from the International Conference of Harmonization (ICH), and being fully compliant to major international regulations such as the FDA (USA), Health Canada, EMA (Europe). For further information, please visit http://www.innovaderm.ca.
About Medrio
Medrio is the leading provider of eClinical technology for early-phase pharma, device, and diagnostics clinical trials. Founded in 2005, the company's cloud-based EDC, eSource, eConsent, and ePRO solutions deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient reported outcome responses. Study sponsors and contract research organizations have used Medrio extensively in clinical trials across a wide array of therapeutic areas, with notable success in oncology, infectious disease, and more. Medrio has extensive experience in all study phases and leads the market in early-phase trials. The company serves over 500 customers globally, with headquarters in San Francisco and offices in numerous domestic and international locations. For more information, please visit http://www.medrio.com.
SOURCE Medrio
Share this article